PubMed ID:
19052125
Public Release Type:
Journal
Publication Year: 2008
Affiliation: Division of Gastroenterology and Hepatology, Department of Internal Medicine, Saint Louis University School of Medicine, 3635 Vista Ave., St. Louis, MO 63110, USA. dibiscam@slu.edu
DOI:
https://doi.org/10.1056/NEJMoa0707615
Authors:
Hoofnagle JH,
Fontana RJ,
Chung RT,
Ghany MG,
Lee WM,
Bonkovsky HL,
Seeff LB,
Kleiner D,
Sterling RK,
Bacon B,
Banner BF,
Bell MC,
Bhan AK,
Brunt EM,
Chen FY,
Chung M,
Contos MJ,
Cormier M,
Craig JR,
Crowder N,
Curto TM,
Davis GL,
DeSanto J,
Di Bisceglie AM,
Dienstag JL,
Elbein R,
Everhart JE,
Everson GT,
Garcia-Tsao G,
Giansiracusa D,
Goodman ZD,
Govindarajan S,
Greenson JK,
Gretch DR,
HALT-C Trial Investigators,
Haynes-Williams V,
Hoefs JC,
Hofmann C,
Jamal MM,
Jones CB,
Kelley M,
King D,
Kugelmas M,
Kutner M,
Lemon SM,
Liang TJ,
Lindsay KL,
Lok AS,
Malet PF,
Massey LJ,
McKinley C,
Mihova MS,
Mills AS,
Milstein SL,
Molchen WA,
Morgan TR,
Morishima C,
Naishadham D,
Nash SR,
Neuschwander-Tetri B,
Padmanabhan L,
Park C,
Park Y,
Perrillo RP,
Reid AE,
Richtmyer PA,
Rivera E,
Robuck PR,
Rogers TE,
Shankar R,
Sheik M,
Shelton J,
Shiffman ML,
Smith P,
Snow KK,
Stoddard AM,
Szabo G,
Tran D,
Wright EC
Studies:
The Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis Trial
In patients with chronic hepatitis C who do not have a response to antiviral treatment, the disease may progress to cirrhosis, liver failure, hepatocellular carcinoma, and death. Whether long-term antiviral therapy can prevent progressive liver disease in such patients remains uncertain.